New Email from the company this morning....should be

New Post Public Reply Private Reply Replies (3) Message Board

Mar 29, 2013 at 11:05 AM

New Email from the company this morning....should be excellent for increasing the exposure for both CTIX and its primary drug..Kevetrin!!!!

Cellceutix Selected for Poster Presentation on Kevetrin at 2013 ASCO Meeting

BEVERLY, MA – Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces that the Company’s abstract on Kevetrin, Cellceutix’s flagship cancer drug candidate in clinical trials at Dana-Farber Cancer Center, has been accepted for poster presentation at the 2013 American Society of Clinical Oncology (“ASCO”) Annual Meeting. The annual ASCO meeting is being held in Chicago, Illinois from May 31 through June 4, 2013.

The Company’s abstract titled, “A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors,” was selected for presentation during the “General Poster Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics” portion of the symposium. The authors of the poster presentation include clinical and laboratory physicians and staff involved in the study from Dana Farber, Beth Israel Deaconess, and Massachusetts General Hospital, along with Cellceutix scientists.

Cellceutix was informed that the Scientific Program Committee and ASCO Leadership received more than 5,300 submissions for poster consideration at this year’s meeting.

“We are proud to have been selected to present our research on Kevetrin to the scientific community at ASCO, especially considering the large number applicants this year,” commented Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. “We are particularly pleased to have been selected for presenting during the high-profile General Poster Session, which allots us additional time for our abstract and extra time for a question and answer session. We receive many inquiries about Kevetrin and its progression in clinical trials and this year’s ASCO meeting provides a fantastic platform for us to share the research with our peers.”

About Kevetrin™

As a completely new class of chemistry in medicine, Kevetrin™ has significant potential to be a major breakthrough in the treatment of solid tumors. Mechanism of action studies showed Kevetrin's unique ability to affect both wild and mutant types of p53 (often referred to as the "Guardian Angel Gene" or the "Guardian Angel of the Human Genome") and that Kevetrin strongly induced apoptosis (cell death), characterized by activation of Caspase 3 and cleavage of PARP. Activation of p53 also induced apoptosis by inducing the expression of p53 target gene PUMA. p53 is an important tumor suppressor that acts to restrict proliferation by inducing cell cycle checkpoints, apoptosis, or cellular senescence.

In more than 50 percent of all human carcinomas, p53 is limited in its anti-tumor activities by mutations in the protein itself. Currently, there are greater than 10 million people with tumors that contain inactivated p53, while a similar number have tumors in which the p53 pathway is partially abrogated by inactivation of other signaling components. This has left cancer researchers with the grand challenge of searching for therapies that could restore the protein's protective function, which Kevetrin appears to be doing the majority of the time.

Further information on the clinical trial, titled "A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors," is available at: http://clinicaltrials.gov/ct2/show/NCT0166400...amp;rank=1

About Cellceutix

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". It is an emerging bio-pharmaceutical company focused on the development of its pipeline of compounds targeting areas of unmet medical need. Our flagship compound, Kevetrin™, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers which have proven resistant to today's cancer therapies (drug-resistant cancers). Cellceutix also owns the rights to seven other drug compounds, including KM-133, which is in development for psoriasis, and KM-391 for the treatment of the core symptoms of autism. More information is available on the Cellceutix web site at www.cellceutix.com.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Factors that may impact Cellceutix's success are more fully disclosed in Cellceutix's most recent public filings with the U.S. Securities and Exchange Commission.

Cellceutix Corp.
Leo Ehrlich

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CHiQ Secures AI Award, Elevates Smart Home Living

CHiQ's Big Win in the AI Game In a world where technology rarely stops spinning, CHiQ has carved its own commendable niche. Snagging the AI Home Ecosystem Brand Award at IFA 2026 in Berlin, the brand's knack for pioneering AI tech isn't just a footnote—it's the whole story. The award—enough to make your competitors green with envy—highlights how far they've come in...

Vobile Teams Up with UNN for AI Factories in Brunei

Delving into Vobile's Latest Strategic Move Vobile, a heavyweight in digital content protection based out of Santa Clara, California, has hit the headlines with a new venture. They've inked a strategic cooperation and commercial agreements with Unified National Networks (UNN) of Brunei Darussalam to construct AI factories. This ain't your run-of-the-mill news, folks. It's...

AI: Game-Changer for IT Budgets & Productivity Gains

AI's Potential to Transform IT Operations You ever feel like IT departments are just stuck on repeat, burning through cash and time just to keep the lights on? It's a common gripe, and Info-Tech Research Group's latest blueprint drives this home, highlighting that routine IT chores eat up a staggering 83% of budgets and 66% of staff's ticking hourglass. Now, who wouldn't...

Acepodia's ACE723 Clears FDA Hurdle for Hepatocellular Push

Unexpected Developments from Acepodia Folks keeping a keen eye on the biotech scene might just raise an eyebrow at Acepodia's latest move. The FDA has given their nod to ACE723, an ambitious dual-payload antibody-drug conjugate (ADC) designed to wrangle with those stubborn cases of unresectable or metastatic hepatocellular carcinoma (HCC). This isn't just another day in...

Woodland Direct Expands West with Reno Facility

Woodland Direct Takes a Bold Step Westward It's no small feat when a company's growing pains turn into growing gains, yet that's exactly what Woodland Direct has managed to pull off with their latest expansion strategy. The Auburn Hills-based e-commerce juggernaut, synonymous with high-quality fire products, just cut the ribbon on a sparkling new 47,000-square-foot...

Parents Champion Meta's Online Safety Agreement

Any old-timer in the market game will tell you this: safeguarding the next generation runs deeper than just chasing profits. A recent poll by the Coalition to Empower our Future reveals something that ain’t too surprising if you’ve been paying attention. Parents all over the nation are nodding along to Meta’s new move to bolster online protections for younger folks....

Orbis Celebrates 20 Years of Eye Care in Macau

Celebrating Two Decades of Eye Health Innovation Orbis, a name synonymous with eye care worldwide, has hit a remarkable milestone. Celebrating two decades of commitment to eye health in Macau, they've rolled out their Flying Eye Hospital with a mission of profound impact. This isn't just about a fancy airplane; it’s about real, lasting change through training projects...

Primero Gains Global Edge with Win Systems Buy

Here's the move: Primero Games, the U.S.-based gaming maestro, just grabbed a hefty piece of the puzzle with their acquisition of Win Systems' Gaming Division. Not two companies merging into obscurity, but a strategic maneuver aiming to scatter new seeds in Latin America and the Caribbean with over 3,000 gaming positions primed and ready. What's in the Pot? You've got...

GlocalMe Unveils Mobile Connectivity Innovations at IFA 2026

Stepping into the Connectivity Future at IFA 2026 GlocalMe, a name synonymous with global mobile connections, made a splash at the IFA 2026 in Berlin. Equipped with a lineup built for the future, their presentation focused on lifestyle gadgets designed for constant online access. In a world where digital connection feels as vital as air, they've aligned perfectly with the...

Baseus Debuts Innovations at IFA 2026: Earbuds to Security

Baseus Pumps New Blood into Tech Gadgets Well, if you're looking for some fresh tech pumping in from Berlin, Baseus tossed out some intriguing gizmos at IFA 2026 that'll perk up your ears. We're looking at an evolution from a brand that's clawed its way from everyday accessories to a full-blown tech ecosystem—pretty ambitious, if you ask me. Baseus isn't playing small...